Bota, SAlves, PConstantino, CMaia, R2023-09-112023-09-112019BMJ Case Rep . 2019 Apr 29;12(4):e227653http://hdl.handle.net/10400.17/4691Hypereosinophilic syndromes are rare in children. Sporadic, mild-severity FIP1L1-platelet-derived growth factor receptor α (PDGFRα) rearrangement cases have been reported, mainly in boys. We present the case of a 5-year-old girl referred from her African country of birth, due to severe constitutional symptoms, multifocal bone pain, headache, gastrointestinal complaints, cardiomyopathy and unexplained hypereosinophilia. She presented multiple end-organ diseases and striking bone involvement. Although she had a positive serology for Strongyloides stercoralis, extensive evaluation detected a FIP1L1-PDGFRA fusion gene. Systemic corticosteroids and low-dose imatinib were started and the child became asymptomatic. After 9 months of treatment, FIP1L1-PDGFRA was no longer detected.engAdrenal Cortex Hormones / administration & dosageAdrenal Cortex Hormones / therapeutic use*Africa / epidemiologyAlbendazole / administration & dosageAlbendazole / therapeutic useAnthelmintics / therapeutic useAntiparasitic Agents / therapeutic useBone Diseases / diagnostic imagingBone Diseases / pathologyChild, PreschoolDrug CombinationsHypereosinophilic Syndrome / drug therapyHypereosinophilic Syndrome / genetics*Hypereosinophilic Syndrome / pathologyImatinib Mesylate / administration & dosageImatinib Mesylate / therapeutic useIvermectin / administration & dosageIvermectin / therapeutic useOncogene Proteins, FusionProtein Kinase Inhibitors / therapeutic useRare diseasesReceptor, Platelet-Derived Growth Factor alphaStrongyloides stercoralis / immunologyStrongyloidiasis / complicationsStrongyloidiasis / diagnosisStrongyloidiasis / parasitology*Treatment OutcomemRNA Cleavage and Polyadenylation FactorsHDE IMAHDE PEDjournal article10.1136/bcr-2018-227653